Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Paroxetine vs PAXIL in Healthy Adults
NCT04311463Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paroxetine in anxiety disorders (2 arms), sponsored by GSK. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Concentration-time Curve From Time Zero to Last Measurable Concentration and 4 more. Started Dec 2020; status: completed.
02
Drugs
paroxetine
03
Conditions
anxiety disorders
Beyond the preview
Go deeper on NCT04311463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311463.